Skip to content
Research Article Open access CC BY 4.0

Methods of Diagnosis a Preferential Advantage in COVID-19: A Mini Review

Neha Saini, Prem Pandey, Mandar Shirolkar, Atul Kulkarni

Journal of Pharmaceutical Research International · pp. 173–179 · Published 4 Sep 2021

10.9734/jpri/2021/v33i43A32476

Abstract

Humanity is going through never seen before health crisis due to the outbreak of novel coronavirus or Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). There are 24.02 million cases and 0.82 million deaths worldwide as of 26th August 2020 due to deadly infection of COVID-19. The disease has been spreading exponentially (R-naught number: 3) and has challenged even the best healthcare infrastructure in the world. With the progression of the disease, the countries shifted the focus from cure to diagnosis and containment to flatten the curve. The review shows that the disease is spreading exponentially while the resources are still limited. We focus upon the probable vectors of the virus, different diagnostic methods with advantages & limitations, and the way forward. This review article covers the different diagnostic methods with more advantages, limitations, and the future sneak-peek into the forthcoming developments for the diagnostic processes such as RT-PCR (Reverse Transcription Polymerase chain reaction).

SARS-CoV-2 serology RT-PCR COVID-19 CT-scan X-ray coronavirus and ultrasound

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

5

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.